- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
aTyr Pharma Inc (ATYR)
aTyr Pharma Inc stock price live, this page displays NASDAQ ATYR stock exchange data. View the ATYR premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the aTyr Pharma Inc real time stock price chart below.
What Is the aTyr Pharma Inc Stock Price Today?
The aTyr Pharma Inc stock price today is 0.824.
What Is the Stock Symbol for aTyr Pharma Inc?
The stock symbol for aTyr Pharma Inc is "ATYR."
What Stock Exchange Does aTyr Pharma Inc Trade On?
aTyr Pharma Inc is listed and trades on the NASDAQ stock exchange.
Is aTyr Pharma Inc a Good Stock to Buy?
Determining whether aTyr Pharma Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ATYR quote. (ISIN: US0021202025)
What Is the aTyr Pharma Inc Stock Price Today?
The aTyr Pharma Inc stock price today is 0.824.
What Is the Stock Symbol for aTyr Pharma Inc?
The stock symbol for aTyr Pharma Inc is "ATYR."
What Stock Exchange Does aTyr Pharma Inc Trade On?
aTyr Pharma Inc is listed and trades on the NASDAQ stock exchange.
Is aTyr Pharma Inc a Good Stock to Buy?
Determining whether aTyr Pharma Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ATYR quote. (ISIN: US0021202025)
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
0.820
0.888
52 wk Range
0.640
7.290
ATYR is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
0.8200.888
52 wk Range
0.6407.290
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
ATYR Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Neutral
Price Target
1.750
Upside
+112.38%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Quickly burning through cash
- Life Tech Corp receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Life Tech Corp receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Life Tech Corp receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- Life Tech Corp receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Life Tech Corp receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Life Tech Corp receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Life Tech Corp receives Investment Bank Analyst Rating Update
- Investing.com
Pro
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
aTyr Pharma Inc Company Profile
aTyr Pharma, Inc., a clinical stage biotechnology company, engages in the discovery and development of product candidates that translate tRNA synthetase biology into new therapies for fibrosis and inflammation in the United States. Its lead therapeutic candidate efzofitimod, a selective modulator of NRP2 that is in Phase 3 clinical trial for the treatment of pulmonary sarcoidosis; Phase 2 clinical trial to treat Sarcoidosis and systemic sclerosis- interstitial lung disease (ILDs); and treatment of other ILDs, such as chronic hypersensitivity pneumonitis (CHP) and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase, which is in preclinical development for the treatment of fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California.
aTyr Pharma Inc SWOT Analysis
Efzofitimod's Promise | Explore aTyr Pharma's lead candidate for pulmonary sarcoidosis, currently in Phase 3 trials, with potential to revolutionize interstitial lung disease treatment |
Market Opportunity | Delve into the substantial market for pulmonary sarcoidosis treatments, with an estimated 200,000 patients in the US alone seeking alternatives to corticosteroids |
Financial Outlook | Uncover aTyr's solid financial position with $87.3M in cash, supporting ongoing clinical programs. Analyst price targets range from $11 to $16 per share |
Future Catalysts | Anticipate key data readouts in 2025, including proof-of-concept for SSc-ILD and Phase 3 results for pulmonary sarcoidosis, potentially transforming aTyr's market position |
aTyr Pharma Inc Earnings Call Summary for Q4/2024
- aTyr Pharma Q4 2024 EPS of -$0.18 beat expectations of -$0.23, with $75.1M cash on hand and $200K revenue from collaborations
- Phase III EFSOFIT study enrollment completed; top-line data expected Q3 2024 for lead candidate Esofitamod in pulmonary sarcoidosis
- Stock rose 12.39% in regular trading but fell 9.77% after hours; analysts maintain strong buy consensus with $9-$35 price targets
- R&D expenses of $54.4M reflect ongoing investment in therapeutic candidates; company exploring additional indications and pipeline development
- CEO Sanjay Shukla emphasized scientific advancements and potential impact across medical fields; EFSOFIT study maintains 90% statistical power
Last Updated: 2025-03-13, 06:18 p/m
Read Full TranscriptCompare ATYR to Peers and Sector
Metrics to compare | ATYR | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipATYRPeersSector | |
|---|---|---|---|---|
P/E Ratio | −1.1x | −6.9x | −0.5x | |
PEG Ratio | −0.15 | 0.16 | 0.00 | |
Price/Book | 1.2x | 5.1x | 2.6x | |
Price / LTM Sales | 425.2x | 11.8x | 3.2x | |
Upside (Analyst Target) | 21.4% | 46.1% | 51.4% | |
Fair Value Upside | Unlock | 5.6% | 8.5% | Unlock |
Analyst Ratings
3 Buy
7 Hold
0 Sell
Ratings:
10 analysts
Overall Consensus
Neutral
Analysts 12-Month Price Target:
Average 1.750
(+112.38% Upside)
Earnings
Latest Release
Mar 05, 2026
EPS / Forecast
-0.14 / -0.183
Revenue / Forecast
-- / 25.00K
People Also Watch
FAQ
What Is the aTyr Pharma (ATYR) Stock Price Today?
The aTyr Pharma stock price today is 0.824 USD.
What Stock Exchange Does aTyr Pharma Trade On?
aTyr Pharma is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for aTyr Pharma?
The stock symbol for aTyr Pharma is "ATYR."
What Is the aTyr Pharma Market Cap?
As of today, aTyr Pharma market cap is 80.790M USD.
What Is aTyr Pharma's Earnings Per Share (TTM)?
The aTyr Pharma EPS (TTM) is -0.797.
When Is the Next aTyr Pharma Earnings Date?
aTyr Pharma will release its next earnings report on May 13, 2026.
From a Technical Analysis Perspective, Is ATYR a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has aTyr Pharma Stock Split?
aTyr Pharma has split 1 times.
How Many Employees Does aTyr Pharma Have?
aTyr Pharma has 59 employees.
What is the current trading status of aTyr Pharma (ATYR)?
As of Mar 07, 2026, aTyr Pharma (ATYR) is trading at a price of 0.824 USD, with a previous close of 0.902 USD. The stock has fluctuated within a day range of 0.820 USD to 0.888 USD, while its 52-week range spans from 0.640 USD to 7.290 USD.
What Is aTyr Pharma (ATYR) Price Target According to Analysts?
The average 12-month price target for aTyr Pharma is 1.750 USD, with a high estimate of 3.5 USD and a low estimate of 1 USD. 3 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Neutral. The stock has an +112.38% Upside potential.
What Is the ATYR After Hours Price?
ATYR's last after hours stock price is 0.841 USD, the stock has decreased by 0.017, or 2.050%.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.